CSChristoph H. Saely

Christoph H. Saely

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christoph H. Saely has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neurological Biomarker Analysis Reveals Smoking-Related GFAP Alterations Independent of Sleep Apnea

    by Ursula Rudin, Kirsten Grossmann, Ornella C. Weideli, Julia Telser, Selina Haselmann, Christoph H. Saely, Jens Kuhle, Pascal Benkert, Pascal Meyre, David Conen, et al.

    Background: Obstructive sleep apnea (OSA) and smoking are associated with oxidative stress, neuronal damage and cardiovascular risk. This study investigated whether subclinical sleep apnea (SSA) - undiagnosed sleep-disordered breathing - or smoking exposure and nicotine dependence are associated with serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in young, healthy adults. Method: This cross-sectional analysis included 1,125 participants from the population-based GAPP cohort (mean age 34.4 years; 51.8% female). SSA was defined as an oxygen desaturation index (ODI; number of ≥4% oxygen desaturations per hour) and/or a respiratory event index (REI; number of apneas and hypopneas per hour) of ≥5. Smoking exposure and nicotine dependence was assessed by smoking years, pack-years, and the Fagerström Test for Nicotine Dependence (FTND). Associations with serum GFAP and NfL levels were investigated using ANCOVA models adjusted for relevant confounders. Results: SSA was present in 4.5% of participants. Current and former smoking prevalence were 20.8% and 22%, respectively. GFAP levels were higher among participants with SSA, but neither GFAP nor NfL was significantly associated with SSA. In contrast, smoking exposure and nicotine dependence were inversely associated with GFAP concentrations, with smoking years remaining significant across adjusted models, whereas NfL levels showed no significant associations with smoking measures. Conclusion: In young, healthy adults, SSA was not associated with GFAP or NfL levels, whereas smoking measures were independently associated with lower GFAP concentrations but not with NfL levels, suggesting smoking-related biological processes may affect astrocytic and axonal biomarkers differently in early adulthood.

  • Open Access

    Anti-SARS-CoV-2 Antibodies versus Vaccination Status in CAD Patients with COVID-19: A Prospective, Propensity Score-Matched Cohort Study

    by Sylvia Mink, Heinz Drexel, Andreas Leiherer, Janne Cadamuro, Wolfgang Hitzl, Matthias Frick, Patrick Reimann, Christoph H. Saely, Peter Fraunberger

    Objectives: Despite the currently prevailing, milder Omicron variant, coronary artery disease (CAD) patients constitute a major risk group in COVID-19, exhibiting 2.6 times the mortality risk of non-CAD patients and representing over 22% of non-survivors. No data are currently available on the efficacy of antibody levels in CAD patients, nor on the relevance of vaccination status versus antibody levels for predicting severe courses and COVID-19 mortality. Nor are there definitive indicators to assess if individual CAD patients are sufficiently protected from adverse outcomes or to determine the necessity of booster vaccinations. Methods: A prospective, propensity-score-matched, multicenter cohort study comprising 249 CAD patients and 903 controls was conducted. Anti-SARS-CoV-2-spike antibodies were measured on hospital admission. Prespecified endpoints were in-hospital mortality, intensive care, and oxygen administration. Results: After adjustment for potential confounders, CAD patients exhibited 4.6 and 6.1-times higher mortality risks if antibody levels were p < 0.001; 6.147, 95%CI 2.529–14.941, p < 0.001). Risk of intensive care was 3.7 and 4.0 (p = 0.003; p < 0.001), and risk of oxygen administration 2.6 and 2.4 times higher below these thresholds (p = 0.004; p = 0.010). Vaccination status was a weaker predictor of all three outcomes than both antibody thresholds. Conclusion: Antibody levels are a stronger predictor of outcome in CAD patients with COVID-19 than vaccination status, with 1200 BAU/mL being the more conservative threshold. Measuring anti-SARS-CoV-2 antibodies in CAD patients may ensure enhanced protection by providing timely booster vaccinations and identifying high-risk CAD patients at hospital admission.

  • Open Access

    Current Practices of Medication Plans in Austrian Patients Undergoing Coronary Angiography: An In-Depth Analysis

    by Johannes B. Vogel, Magdalena Neyer, Pascal Elsner, Alexander Vonbank, Thomas Plattner, Christoph H. Saely, Andreas Leiherer, Heinz Drexel

    A complete medication plan (MPlan) increases medication safety and adherence and is crucial in care transitions. Countries that implemented a standardized MPlan reported benefits on patients’ understanding and handling of their medication. Austria lacks such a standardization, with no available data on the issue. Objective: This study aimed to investigate the current state of all medication documentations (MDocs) at hospital admission in a population at high risk for polypharmacy in Austria. Methods: We enrolled 512 consecutive patients undergoing elective coronary angiography. Their MDocs and medications were recorded at admission. MDocs were categorized, whereby a MPlan was defined as a tabular list including medication name, dose, route, frequency and patient name. Results: Out of 485 patients, 55.1% had an MDoc (median number of drugs: 6, range 2–17), of whom 24.7% had unstructured documentation, 18.0% physicians’ letters and 54.3% MPlans. Polypharmacy patients did not have a MDoc in 31.3%. Crucial information as the patients’s name or the originator of the MDoc was missing in 31.1% and 20.4%, respectively. Patients with MDoc provided more comprehensive medication information (p = 0.019), although over-the-counter-medication was missing in 94.5% of MDocs. A discrepancy between the MPlan and current medication at admission existed in 64.4%. In total, only 10.7% of our patient cohort presented an MPlan that was in accordance with their current medication. Conclusion: The situation in Austria is far from a standardized MPlan generated in daily routine. Numerous MPlans do not represent the current medication and could pose a potential risk for the effectiveness and safety of pharmacotherapy.


  • Open Access

    Coronary Event Risk Test (CERT) as a Risk Predictor for the 10-Year Clinical Outcome of Patients with Peripheral Artery Disease

    by Andreas Leiherer, Axel Muendlein, Christoph H. Saely, Kathrin Geiger, Eva-Maria Brandtner, Christine Heinzle, Stella Gaenger, Sylvia Mink, Reijo Laaksonen, Peter Fraunberger, et al.

    (1) Background: Ceramides are a new kind of lipid biomarker and have already been demonstrated to be valuable risk predictors in coronary patients. Patients with peripheral artery disease (PAD) are a population with a worse prognosis and higher mortality risk compared to coronary artery disease (CAD) patients. However, the value of ceramides for risk prediction in PAD patients is still vague, as addressed in the present study. (2)Methods: This observational study included 379 PAD patients. The primary endpoint was all-cause mortality at 10 years of follow-up. A set of ceramides was measured by LC-MS/MS and combined according to the Coronary Event Risk Test (CERT) score, which categorizes patients into one of four risk groups (low risk, moderate risk, high risk, very high risk). (3) Results: Kaplan–Meier survival curves revealed that the overall survival of patients decreased with the increasing risk predicted by the four CERT categories, advancing from low risk to very high risk. Cox regression analysis demonstrated that each one-category increase resulted in a 35% rise in overall mortality risk (HR = 1.35 [1.16–1.58]). Multivariable adjustment, including, among others, age, LDL-cholesterol, type 2 diabetes, and statin treatment before the baseline, did not abrogate this significant association (HR = 1.22 [1.04–1.43]). Moreover, we found that the beneficial effect of statin treatment is significantly stronger in patients with a higher risk, according to CERT. (4) Conclusions: We conclude that the ceramide-based risk score CERT is a strong predictor of the 10-year mortality risk in patients with PAD.


  • Open Access

    Age and professional experience as determinants of the utilization of psychoneuroimmunological research in clinical practice: An exploratory study

    by Christian Msc Mareth, Ulrich K. Fetzner, Christoph H. Saely

    The immune system is affected by psychosocial stimuli and plays a major role in the development of various diseases. Psychoneuroimmunology (PNI)-based interventions may positively influence the disease course; however, the impact of PNI research findings on clinical practice differs depending on the medical specialties involved. A comprehensive overview of the use of PNI research findings in clinical practice is currently lacking. This exploratory study aimed to provide insight into the dissemination of PNI research findings and their practical applications among clinical practitioners. Data was collected from 50 physicians using an ad hoc online questionnaire. We invited participants to take part in our online survey via an article in the DocCheck Newsletter, a German-language newsletter for physicians. Bivariate nonparametric correlation analysis (Spearman correlation) were used to explore the relationship between independent variables (age, sex, medical specialty, professional experience, and clinical environment) and dependent variables (six questionnaire items concerned with awareness, relevance, and utilization of PNI concepts). While 46% of respondents believed that PNI research findings were relevant to patient treatment, only 22% used PNI-based interventions as part of their therapeutic regimen. Furthermore, 90% of participants could not refer their patients to therapists offering PNI-based interventions. Moderately positive correlations were identified between the increasing age (rs = .48, P < .001) and increasing amount of professional experience (rs = .34, P = .02) of study participants and awareness of the theoretical foundations of PNI research. Although there is some awareness of PNI among medical practitioners, there appears to be a clear barrier inhibiting the implementation of research findings in current treatment practices. Therefore, it is necessary to examine the impact of increasing age and professional experience on the utilization of PNI-based interventions in patient care.


  • Open Access

    Association between Lipid Levels, Anti-SARS-CoV-2 Spike Antibodies and COVID-19 Mortality: A Prospective Cohort Study

    by Sylvia Mink, Christoph H. Saely, Matthias Frick, Andreas Leiherer, Heinz Drexel, Peter Fraunberger

    Background: Recent studies suggest that both lipid levels and anti-severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) antibody levels are associated with outcome in coronavirus disease 2019 (COVID-19). While both parameters have separately been implicated in the neutralization and clearance of pathogens during severe infections, it is currently unclear whether the interplay of these parameters affects outcome in COVID-19. We therefore aimed to determine whether there was a relationship between lipoproteins, anti-SARS-CoV-2 antibodies, and COVID-19 mortality. Methods: In this prospective, multicenter cohort study, we recruited 1152 hospitalized patients with COVID-19 from five hospitals. Total cholesterol (TC), LDL-C, HDL-C, triglycerides, and anti-SARS-CoV-2 spike antibodies were measured on hospital admission. The investigated endpoint was in-hospital mortality. Results: LDL-C, HDL-C, and TC were significantly lower in non-survivors than in survivors (mg/dL, 95%CI; 56.1, 50.4–61.8 vs. 72.6, 70.2–75.0, p < 0.001; 34.2, 31.7–36.8 vs. 38.1, 37.2–39.1, p = 0.025; 139.3, 130.9–147.7 vs. 157.4, 54.1–160.6, p = 0.002). Mortality risk increased progressively with lower levels of LDL-C, HDL-C, and TC (aOR 1.73, 1.30–2.31, p < 0.001; 1.44, 1.10–1.88, p = 0.008; 1.49, 1.14–1.94, p < 0.001). Mortality rates varied between 2.1% for high levels of both LDL-C and anti-SARS-CoV-2 antibodies and 16.3% for low levels of LDL-C and anti-SARS-CoV-2 antibodies (aOR 9.14, 95%CI 3.17–26.34, p < 0.001). Accordingly, for total cholesterol and anti-SARS-CoV-2 antibodies, mortality rates varied between 2.1% and 15.0% (aOR 8.01, 95%CI 2.77–23.18, p < 0.001). Conclusion: The combination of serum lipid levels and anti-SARS-CoV-2 antibodies is strongly associated with in-hospital mortality of patients with COVID-19. Patients with low levels of LDL-C and total cholesterol combined with low levels of anti-SARS-CoV-2 antibodies exhibited the highest mortality rates.


  • Open Access

    Coronary Event Risk Test (CERT) as Risk Predictor for the 10-Year Clinical Outcome of Patients with Peripheral Artery Disease

    by Andreas Leiherer, Axel Muendlein, Christoph H Saely, Kathrin Geiger, Eva-Maria Brandtner, Christine Heinzle, Stella Gaenger, Reijo Laaksonen, Peter Fraunberger, Heinz Drexel

    Background: Ceramides are a new kind of lipid biomarkers and have already been demonstrated to be valuable risk predictors in coronary patients. Patients with peripheral artery disease (PAD) are a population with worse prognosis and higher mortality risk compared to coronary artery disease (CAD) patients. However, the value of ceramides for risk prediction in PAD patients is still vague and has been addressed in the present study. Methods: This observational study included 379 PAD patients. The primary endpoint was all-cause mortality at 10 years of follow-up. A set of ceramides was measured by LC-MS/MS and combined according to the coronary event risk test (CERT) score which categorizes patients into one of four risk groups (low risk, moderate risk, high risk, very high risk). Results: Kaplan Meier survival curves revealed that the overall survival of patients has decreased with the increasing risk predicted by the four CERT categories, advancing from low risk to very high risk. Cox regression analysis demonstrated that every 1-step increase in category resulted in a 35% rise in overall mortality risk (HR=1.35 [1.16-1.58]). Multivariable adjustment, including amongst others age, T2DM, and statin treatment before baseline, did not abrogate this significant association (HR=1.22 [1.04-1.43]). Moreover, we found that the beneficial effect of statin is significantly stronger in patients with a higher risk according to CERT. Conclusion: We conclude that the ceramide-based risk score CERT is a strong predictor of the 10-year mortality risk in patients with PAD.

  • P-tau217 in Alzheimer’s disease

    by Julia Telser, Lorenz Risch, Christoph H. Saely, Kirsten Grossmann, Philipp Werner